These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20865021)

  • 1. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
    Doloff JC; Waxman DJ; Jounaidi Y
    Hum Gene Ther; 2008 Dec; 19(12):1383-400. PubMed ID: 18771358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
    Kurihara T; Brough DE; Kovesdi I; Kufe DW
    J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE; Merron A; Vassaux G; Keith WN
    Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
    Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
    Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
    Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
    Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
    Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
    Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
    Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of an E1A Gene Expression Cassette in an Oncolytic Adenovirus for Efficient Tumor Cell Killing Activity.
    Sakurai F; Nishimae F; Takayama K; Mizuguchi H
    Anticancer Res; 2021 Feb; 41(2):773-782. PubMed ID: 33517282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenovirus based on serotype 3.
    Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
    Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.